Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia

Targeted Oncology

Volumn 13, Issue 4, 2018, Pages 525-532

  Al Salama, Zaina T ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INOTUZUMAB OZOGAMICIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE MANAGEMENT; HUMAN; INFUSION RELATED REACTION; LEUKEMIA RELAPSE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MONOTHERAPY; PHARMACODYNAMIC PARAMETERS; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TUMOR LYSIS SYNDROME; FEMALE; MALE; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 85051701521     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-018-0584-z     Document Type: Review

References (30)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia (version 1.2018). 2018. http://www.nccn.org. Accessed 9 Jul 2018
2. DeAngelo DJ, Stock W, Stein AS, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–80
3. Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13(3):296–301
4. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165–74
5. Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98(5):425–34
6. European Medicines Agency. Besponsa (inotuzumab ozogamicin): EU summary of product characteristics. 2017. https://www.ema.europa.eu. Accessed 9 Jul 2018
7. US FDA. Besponsa (inotuzumab ozogamicin) for injection, for intravenous use: US prescribing information. 2017. https://www.accessdata.fda.gov. Accessed 9 Jul 2018
8. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253–61
9. Pfizer Japan Inc. Besponsa (inotuzumab ozogamicin): Japanese prescribing information. 2018. https://www.pmda.go.jp. Accessed 9 Jul 2018
10. Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77(14):1603–10
11. De Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255–64
12. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14
13. DiJoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240–5
14. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53
15. Jani D, Nowak J, Chen Y, et al. Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia. AAPS Open. 2018; 10.1186/s41120-018-0021-5
16. Garrett M, Ruiz-Garcia A, Parivar K, et al. Characterization of inotuzumab ozogamicin time dependent clearance in relapsed/refractory acute lymphoblastic leukemia patients by nonlinear mixed-effects analysis [abstract no. PI-128]. Clin Pharmacol Ther. 2016;99(Suppl 1):S64–5
17. Advani AS, Jabbour EJ, Stelljes M. Inotuzumab ozogamicin (InO) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the global phase 3 INO-VATE trial: efficacy by MLL status [abstract no. 2557]. Blood. 2017;130(Suppl 1)
18. Advani AS, Jabbour EJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care for relapsed/refractory acute lymphoblastic leukemia in the phase 3 randomized INO-VATE trial: outcomes by salvage treatment phase [abstract]. Blood. 2016;128(22):5188
19. Jabbour E, Advani A, Stelljes M, et al. Prognostic implications of pretreatment cytogenetics in adults with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin [abstract no. P519]. Haematologica. 2017;102(Suppl 2):198
20. Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the global phase 3 INO-VATE trial: efficacy and safety by baseline CD22 expression level [abstract no. 1272]. Blood. 2017;130(Suppl 1)
21. Su Y, Van Oostrum I, Vandendries E, et al. Hospitalization for patients in the United States (US) and European Union (EU) treated with inotuzumab ozogamicin (InO) vs standard of care (SOC) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in a global phase 3 trial [abstract no. e18500]. J Clin Oncol. 2017;35(15 Suppl)
22. van Oostrum I, Su Y, Heeg B, et al. Quality-adjusted life years (QALY) for inotuzumab ozogamicin vs standard of care for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) [abstract no. e18506]. J Clin Oncol. 2017;35(15 Suppl)
23. Kantarjian HM, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin (InO) vs standard of care (SC) in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): long-term results of the phase 3 INO-VATE study [abstract no. 2574]. Blood. 2017;130(Suppl 1)
24. European Medicines Agency. Besponsa (inotuzumab ozogamicin): EU assessment report. 2017. https://www.ema.europa.eu. Accessed 9 Jul 2018
25. Jabbour EJ, DeAngelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018;124(8):1722–32
26. Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387–e98
27. Kantarjian HM, Su Y, Jabbour EJ, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151–60
28. Cassaday RD, De Angelo DJ, Martinelli G, et al. Extensive safety profile of inotuzumab ozogamicin (Ino) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial [abstract no. 7029] J Clin Oncol. 2018;36(Suppl)
29. Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v69–82
30. National Institute for Health and Care Excellence (NICE). Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: final appraisal determination. 2017. https://www.nice.org.uk. Accessed 9 Jul 2018